RxDoctor Payments Data

James Tran, MD

Cardiovascular Disease · Westminster, CANPI 1598781346

Payments from drug & device makers

$35,368in general payments, 2019–2025

Across 765 payments — averaging $46.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$12K
  • Bayer$6K
  • AstraZeneca$3K
  • Johnson & Johnson$2K
  • Amgen$2K
  • Gilead$1K
  • plus $10K from 32 others

What the payments were for

  • Consulting fees$3,57610%
  • Speaking & faculty fees$9,17526%
  • Travel & lodging$4601%
  • Food & beverage$21,89662%
  • Education$2621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,368 in reported general payments places this provider in the 85th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$644,036
Medicare patients
909
Services billed
9,575

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KerendiaFinerenone566$627,106
VascepaIcosapent Ethyl804$471,438
LinzessLinaclotide462$422,902
BrilintaTicagrelor499$377,132
EliquisApixaban361$355,351
FarxigaDapagliflozin Propanediol276$288,350
EntrestoSacubitril/Valsartan225$222,873
CreonLipase/Protease/Amylase106$202,497
Icosapent Ethyl218$65,074
Repatha SureclickEvolocumab107$58,656
XareltoRivaroxaban53$56,566
Praluent PenAlirocumab103$52,647
Dexlansoprazole DrDexlansoprazole103$31,196
DapagliflozinDapagliflozin Propanediol44$29,977
JardianceEmpagliflozin32$27,920

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta, Farxiga, Breztri Aerosphere$3,348$692,955803 claims
BayerKerendia$5,780$627,106566 claims
AbbVieLinzess, Creon$1,080$625,399568 claims
PfizerEliquis$89$355,351361 claims
NovartisEntresto$11,623$222,873225 claims
Johnson & JohnsonXarelto$2,123$56,56653 claims
Boehringer IngelheimJardiance, Tradjenta, Pradaxa$929$49,10760 claims
Lexicon Pharmaceuticals, Inc.Inpefa$242$13,40623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Westminster

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →